Mark Anthony McCamish - 30 Jul 2024 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
30 Jul 2024
Net transactions value
$0
Form type
4
Filing time
01 Aug 2024, 16:32:04 UTC
Previous filing
08 Jan 2024
Next filing
31 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVDL Ordinary Shares Award $0 +11,000 $0.000000 11,000 30 Jul 2024 Direct F1
holding AVDL Ordinary Shares 67,025 30 Jul 2024 By Matthew 5 LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +11,000 $0.000000 11,000 30 Jul 2024 Ordinary Shares 11,000 $16.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.
F2 Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
F3 The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.